City of Hope shared a post on LinkedIn:
“For Barbara Andes, receiving daraxonrasib, a promising new treatment for pancreatic cancer, feels like a blessing and a miracle.
Barbara is one of the first patients in the country to receive this emerging therapy while it is still being studied for FDA approval — and one of the first at City of Hope. This could mean more time with her children, grandchildren and great-grandchildren. More moments to make memories. More opportunities to dream about what’s next, including a trip to Norway she’s eager to take.
For all of us, it’s a reminder of why every breakthrough matters.
She is profoundly grateful to Robert Stone for his leadership and for being there for this pivotal moment and to Dr. Pashtoon Kasi for his clinical expertise, advocacy and compassion.”
Robert Stone, Chief Executive Officer of City of Hope, shared a post on LinkedIn:
“The patient is never the outcome. The patient is our purpose.
Barbara, our City of Hope grateful patient, was one of the first patients to receive Daraxonrasib, a promising new treatment for pancreatic cancer through the FDA’s expanded access program. Standing beside her on such a monumental day was a privilege I will never forget.
I’m deeply grateful she chose to share her story with the world.
Behind every scientific breakthrough is a person, a family and a future worth fighting for. Barbara reminds us why our researchers challenge what’s possible, why our physicians refuse to accept the status quo, and why we continue to invest in discoveries that can change what’s possible for patients today and for generations to come.
Breakthroughs like this are made possible by extraordinary scientists, clinicians and supporters who believe we can do better. The Stephenson Global Pancreatic Cancer Research Institute’s transformational $150 million investment in pancreatic cancer research is helping accelerate that work with urgency.
Barbara’s story is about hope, but it is also about purpose. Our responsibility is to expand access to tomorrow’s breakthroughs while advancing the science that makes them possible. That is how we move closer to ending cancer.
Thank you, Good Morning America, for shining a light on Barbara’s journey and the importance of accelerating new options for patients facing pancreatic cancer.”
You can also read: Daraxonrasib for Pancreatic Cancer: What’s Next?
